Stock Events

Stock Events

Insmed 

$108.57
130
-$1.89-1.71%Friday 07:54

Statistics

Day High
109.74
Day Low
108.57
52W High
139.44
52W Low
92.07
Volume
36
Avg. Volume
-
Mkt Cap
23.82B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 29Expected
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Q3 2026
-1.75
-1.19
-0.62
-0.06
Expected EPS
-0.382735
Actual EPS
-0.46

Financials

-210.54%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
606.42MRevenue
-1.28BNet Income

Analyst Ratings

$192.36Average Price Target
The highest estimate is ⁦220.00⁩.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
92%
Hold
8%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INSM.BOATS. It's not an investment recommendation.
NVIDIA
32
NVDA
Alphabet
23
GOOGL
Microsoft
22
MSFT
Amazon
22
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for cystic fibrosis, a market that Insmed is targeting with its therapies.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences competes in the biopharmaceutical space, focusing on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, overlapping with Insmed's focus on serious and rare diseases.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes with Insmed in the area of cystic fibrosis and other serious health conditions through its robust pipeline of biopharmaceuticals.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is a competitor due to its focus on developing monoclonal antibodies for the treatment of rare diseases, a similar focus area as Insmed.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes with Insmed in the respiratory disease market, including treatments for conditions like asthma and COPD.
Biogen
BIIB
Mkt Cap37.49B
Biogen competes in the biopharmaceutical space focusing on neurological diseases, overlapping with Insmed's interest in rare diseases.
AMGEN
AMGN
Mkt Cap251.94B
Amgen competes with Insmed through its development of treatments for serious illnesses, including those in the respiratory and inflammation areas.
Novartis
NVS
Mkt Cap303.67B
Novartis competes with Insmed in the healthcare sector, focusing on innovative medicines for various diseases, including respiratory.

About

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Show More
CEO
ISIN
US4576693075

Listings

MI
IT
1INSM.MI
XETRA
DE
IM8N.XETRA
STU
DE
IM8N.STU
F
DE
IM8N.F

0 Comments

Share your thoughts

FAQs

What is Insmed stock price today?▼
The current price of INSM.BOATS is $108.57 USD — it has decreased by -1.71% in the past 24 hours. Watch Insmed stock price performance more closely on the chart.
What is Insmed stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Insmed stocks are traded under the ticker INSM.BOATS.
What is Insmed market cap?▼
Today Insmed has the market capitalization of 23.82B
When is the next Insmed earnings date?▼
Insmed is going to release the next earnings report on February 25, 2027.
What were Insmed earnings last quarter?▼
INSM.BOATS earnings for the last quarter are -0.46 USD per share, whereas the estimation was -0.38 USD resulting in a -20.19% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Insmed revenue for the last year?▼
Insmed revenue for the last year amounts to 606.42M USD.
What is Insmed net income for the last year?▼
INSM.BOATS net income for the last year is -1.28B USD.
In which sector is Insmed located?▼
Insmed operates in the Other sector.
When did Insmed complete a stock split?▼
The last stock split for Insmed was on March 3, 2011 with a ratio of 1:10.